[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627322":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":27,"locations":36,"responsibleParty":52,"collaborators":10,"id":55,"slug":10,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":67,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":79,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"East Carolina University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with end-stage kidney disease (ESKD) requiring continuous renal replacement therapy (CRRT).",null,"This cohort will include adult patients with end-stage kidney disease (ESKD) receiving chronic outpatient hemodialysis who are admitted to the Intensive Care Unit (ICU) and require continuous renal replacement therapy (CRRT). Eligible participants must have a mature, functional permanent vascular access used for outpatient hemodialysis, defined as either a functioning arteriovenous fistula (AVF) or a functioning arteriovenous graft (AVG). Patients must meet the inclusion and exclusion criteria prior to enrollment.",[13],"Other: Cannulation of permanent dialysis access, for the purpose of delivering continuous renal replacement therapy.",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Cannulation of permanent dialysis access, for the purpose of delivering continuous renal replacement therapy.","Permanent dialysis access, including arteriovenous fistulas or grafts, will be cannulated using standard dialysis needles for the purpose of delivering continuous renal replacement therapy.\n\nCRRT via arteriovenous access will only be performed in ICU settings where nursing staff have at least one year of ICU experience and have completed both study-specific training and institutional CRRT training. Dialysis nurses will perform cannulation of the arteriovenous access according to the standardized operating procedure.",[9],[20,24],{"name":21,"affiliation":22,"role":23},"Armando F Rodriguez Lopez, MD","ECU Health Medical Center","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":22,"role":26},"Iskra Myers, MD","STUDY_DIRECTOR",[28,33],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Armando Rodriguez Lopez, MD","CONTACT","+19392750483","rodriguezlopeza23@ecu.edu",{"name":25,"role":30,"phone":34,"phoneExt":10,"email":35},"914-282-4448","myersi20@ecu.edu",[37],{"facility":38,"status":10,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"East Carolina University Medical Center","Greenville","North Carolina","27834","United States",{"type":44,"coordinates":45},"Point",[46,47],-77.36635,35.61266,{"lat":47,"lon":46},[50],{"name":21,"role":30,"phone":51,"phoneExt":10,"email":32},"9392750483",{"type":23,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Armando Rodriguez Lopez","Doctor in Medicine","100627322",false,"NCT07447128","Prospective Analysis of Arteriovenous Access (AVA) Use for Continuous Renal Replacement Therapy (CRRT)","Prospective Analysis of Arteriovenous Access Use in Continuous Renal Replacement Therapy, a Feasibility Project","CRRT","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of End-Stage Kidney Disease (ESKD) receiving maintenance chronic hemodialysis\n* Admission to the Intensive Care Unit (ICU)\n* Presence of a functioning arteriovenous fistula (AVF) or arteriovenous graft (AVG)\n* Clinical indication for Continuous Renal Replacement Therapy (CRRT)\n* Score of ≥16 points on the study enrollment screening tool\n\nExclusion Criteria:\n\n* Age under 18 years\n* Arteriovenous access thrombectomy within 30 days prior to study enrollment\n* Documented prolonged bleeding from arteriovenous access within 30 days prior to study enrollment\n* Current dialysis via temporary or tunneled hemodialysis catheter\n* International Normalized Ratio (INR) \\> 3.0\n* Acute liver failure, defined as AST \\> 1000 U\u002FL and\u002For ALT \\> 1000 U\u002FL\n* Platelet count \\\u003C 50,000\u002FµL\n* Evidence of disseminated intravascular coagulation (DIC)\n* Pregnant patients\n* Patients actively attempting to become pregnant","ALL","18 Years",{"count":65,"type":66},50,"ESTIMATED","30 Days","OBSERVATIONAL","Arteriovenous fistula or graft are the ideal hemodialysis access. Nonetheless the most common access type used for Continuous Renal Replacement Therapy (CRRT) is either a temporary or permanent hemodialysis catheter. Recommendations for the use of catheters to deliver CRRT in end stage kidney disease (ESKD) patients are lacking on data and subjective to anecdotal experiences and expert consensus. The repetitive placement of catheters in ESKD patients have shown to increase the chances of central vascular stenosis which is one of the main risk factors that lead to access failure. Also, the repetitive use of dialysis catheters increases the risk for catheter associated infections. Dedicated studies demonstrating the safety and feasibility of using arteriovenous access (AVA) for CRRT are scarce. No screening criteria or algorithm exists to determine the adequate patient and clinical scenario to use AVA for CRRT.\n\nGoals of the study:\n\n1. To develop a standard operating procedure for the use of AVA in CRRT.\n2. Evaluate the safety and efficacy of using AVA for CRRT.",[71,72],"Continuous Renal Replacement Therapy (CRRT)","End Stage Kidney Disease (ESRD)",[74,75,60,76,77,78],"Arteriovenous access","Continuous Renal Replacement Therapy","AVA","ESKD","End Stage Kidney Disease","NOT_YET_RECRUITING","2026-02-27",{"date":82,"type":83},"2026-03-03","ACTUAL",{"date":85,"type":66},"2026-03",{"date":87,"type":66},"2026-09",{"name":5,"class":6},1]